Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News PhaseRx Inc (EM) PZRXQ

Healthcare Biotechnology
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:PZRXQ)

PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares

PR Newswire December 13, 2017

PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding

PR Newswire December 11, 2017

Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Auris Medical Shares Plummet

Benzinga.com  November 28, 2017

Mid-Day Market Update: Thor Industries Surges On Earnings Beat; Momo Shares Plunge

Benzinga.com  November 28, 2017

Mid-Morning Market Update: Markets Open Higher; Arby's To Merge With Buffalo Wild Wings

Benzinga.com  November 28, 2017

PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency

PR Newswire November 28, 2017

PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update

PR Newswire November 9, 2017

Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx – Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire November 2, 2017

PhaseRx to Present at 5th International mRNA Conference

PR Newswire October 31, 2017
View More News ››

Opinion & Analysis (EXPM:PZRXQ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:PZRXQ)

Be the first to post on this bullboard.

Allied Critical Metals Inc.

Allied Critical Metals Inc.

Allied Critical Metals (ACM:CSE) is a Canadian-based mining company focused on the expansion and revitalization of its 100 ...
View More »